Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 4/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | DRD3 | P35462 | 2/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22993390 | 0.87 | KDM4E (0.42) | KDM4EBACE1HTR2CHTR2ADRD2 | |
| SCHEMBL24253343 | 0.84 | BACE1 (0.36) | KDM4EBACE1 | |
| SCHEMBL24253511 | 0.80 | HTR2C (0.35) | BACE1HTR2CHTR2ADRD2DRD3 | |
| SCHEMBL24253542 | 0.79 | HTR2C (0.34) | BACE1HTR2CHTR2ADRD2DRD3 | |
| SCHEMBL22993439 | 0.79 | KDM4E (0.38) | KDM4ESLC6A2SLC6A4SLC6A3 | |
| SCHEMBL26419009 | 0.77 | KDM4E (0.43) | KDM4EBACE1HTR2CHTR2ADRD2 | |
| SCHEMBL24253510 | 0.76 | HTR2A (0.33) | HTR2CHTR2AHTR2B | |
| SCHEMBL24451834 | 0.76 | KDM4E (0.43) | KDM4EBACE1HTR2CHTR2AHTR2B | |
| SCHEMBL24329573 | 0.74 | HTR2C (0.48) | HTR2CHTR2ADRD2DRD3CTSD | |
| SCHEMBL29391452 | 0.73 | MAOA (0.40) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-11613527-B2 | Enzyme inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-03-28 | — | — | US | disclosed |
| US-20220048894-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | KDM4E 1403/4885BACE1 149/4885HTR2C 4421/4885 |
| US-11613527-B2 | Enzyme inhibitors | SERPINB1, KLKB1, SERPINE1 | KDM4E 1403/4885BACE1 149/4885HTR2C 4421/4885 |
| US-20220048894-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | KDM4E 1403/4885BACE1 149/4885HTR2C 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.